GXNPC1

Cerebrovascular disease is one of the top ten leading causes of death in Taiwan, with stroke being the most common. Stroke causes varying degrees of disability, and with no other effective treatments available, patients are often limited to passive rehabilitation. For those with severe conditions who require long-term care, the psychological pressure and financial burden on their caregivers and families undoubtedly make a difficult situation even worse.

Research indicates that stem cells are indeed therapeutic for stroke treatment, highlighting the necessity and urgency of stem cell therapy. GWOXI's new stem cell drug, "GXNPC1 Syiyou," can promote cerebrovascular and nerve regeneration. Confirmed by animal studies, the drug's properties—such as promoting angiogenesis, reducing inflammation, and nerve differentiation—can improve stroke-related disability and enhance coordination, balance, and mobility.

In September 2019, GWOXI collaborated with Hualien Tzu Chi Hospital to initiate a Phase II clinical trial. GXNPC1 is expected to become the first stem cell-based product in Taiwan for the treatment of stroke, offering a new therapeutic option for stroke patients.

Tzu Chi Da Ai Television's documentary "Guardians of Love as Healers: Reborn" (July 22, 2018)

Discovery Channel - "Taiwan's Incredible Showcase: Biomedical Technology" (October 19, 2020)

nstitute for Biotechnology and Medicine Industry (IBMI): A New Stem Cell Drug for Chronic Stroke – Syiyou | GWOXI Stem Cell Applied Technology (June 2, 2022)